Cancer Research· 2017Q1

Discovery of IDO1 Inhibitors: From Bench to Bedside

George C. Prendergast, William P. Malachowski, James B. DuHadaway, Alexander J. Muller

569citations
Q1SCImago
2017year

Short summary

Small-molecule inhibitors of indoleamine 2,3-dioxygenase-1 (IDO1) are emerging as a new class of cancer therapeutics, with indoximod, epacadostat, and navoximod being the first evaluated in clinical trials.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Biological Psychiatry

Biological PsychiatryNeuroscience